Besides, the KEYNOTE-040 study revealed that the median OS was 11.6 months with pembrolizumab, better than standard care with 6.6 months in patients with a PD-L1 tumor proportion score of 50% or higher8. This evidence concerns the gene CD274 and neoplasm.